Literature DB >> 23827936

Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.

J Furin1, G Brigden, E Lessem, M C Becerra.   

Abstract

Tens of thousands of children are sick with multidrug-resistant forms of tuberculosis (MDR-TB), but there are limited child-friendly delivery systems for second-line medications. This case study presents the development of a granular dosing spoon pediatric delivery system for para-aminosalicylic acid. This product is the first of its kind for MDR-TB and could serve as a model for the development of other urgently needed pediatric delivery systems for second-line anti-tuberculosis drugs.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23827936     DOI： 10.5588/ijtld.13.0196

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  3 in total

1.  Topical Aminosalicylic Acid Improves Keratinocyte Differentiation in an Inducible Mouse Model of Harlequin Ichthyosis.

Authors:  Denny L Cottle; Gloria M A Ursino; Lynelle K Jones; Ming Shen Tham; Allara K Zylberberg; Ian M Smyth
Journal:  Cell Rep Med       Date:  2020-11-17

Review 2.  Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.

Authors:  James A Seddon; H Simon Schaaf
Journal:  Pneumonia (Nathan)       Date:  2016-11-24

3.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.